LIÈGE, Belgium--(BUSINESS WIRE)--Eurogentec S.A. (“Eurogentec”) announces today a final agreement for the acquisition of AnaSpec, Inc. (“AnaSpec” or the “Company”), a privately-held proteomics company based in Fremont, California. Founded in 1993, AnaSpec is a leading provider of integrated proteomics solutions for life science research and diagnostics with expertise in peptides synthesis, labeled peptides and antibodies, fluorescent dyes and enzyme activity assays. AnaSpec has developed one of the world’s largest collections of catalog and dye-labeled peptides in the fields of Alzheimer Disease, Multiple Sclerosis and enzyme inhibitor screening. Leveraging its expertise in peptide, antibodies and fluorescent dyes, AnaSpec has established a leading edge portfolio of integrated proteomics solutions such as FRET based assays and SensoLyte™ assays for basic research, high-throughput screening and drug discovery. Furthermore, AnaSpec’s proprietary fluorescent dyes are being used by the world’s leading diagnostic companies to enhance their diagnostic solutions.
